Name | Value |
---|---|
Revenues | 0.0M |
Cost of Revenue | 0.6M |
Gross Profit | -0.6M |
Operating Expense | 55.3M |
Operating I/L | -55.6M |
Other Income/Expense | 7.6M |
Interest Income | 6.2M |
Pretax | -49.4M |
Income Tax Expense | 0.2M |
Net Income/Loss | -49.6M |
Replimune Group, Inc. is a biotechnology company specializing in oncolytic immuno-gene therapies for cancer treatment. Leveraging its proprietary Immunotherapy platform, the company develops product candidates, including RP1, a selectively replicating version of herpes simplex virus 1, currently in Phase I/II clinical trials for solid tumors and Phase II trials for cutaneous squamous cell carcinoma. Additionally, it is working on RP2, a Phase I anti-CTLA-4 antibody-like protein, and RP3, a Phase I immune-activating protein expression therapy to stimulate T cells.